Nipocalimab
Systemic Lupus Erythematosus (SLE)
Key Facts
About johnson-and-johnson-innovative-medicine
Johnson & Johnson Innovative Medicine, established as a clarified entity in 2023 following the Kenvue spin-off, is a global pharmaceutical leader with a mission to transform healthcare through high-impact science. Its strategy integrates deep internal R&D with strategic business development to build a leading pipeline across oncology, immunology, neuroscience, and cardiopulmonary diseases. Recent achievements include the FDA approval of the first-in-class oral peptide ICOTYDE™ for psoriasis and the expansion of its multiple myeloma regimen, demonstrating its capacity for innovation and commercial execution within the J&J conglomerate.
View full company profileAbout johnson-and-johnson-innovative-medicine
Johnson & Johnson Innovative Medicine, established as a clarified entity in 2023 following the Kenvue spin-off, is a global pharmaceutical leader with a mission to transform healthcare through high-impact science. Its strategy integrates deep internal R&D with strategic business development to build a leading pipeline across oncology, immunology, neuroscience, and cardiopulmonary diseases. Recent achievements include the FDA approval of the first-in-class oral peptide ICOTYDE™ for psoriasis and the expansion of its multiple myeloma regimen, demonstrating its capacity for innovation and commercial execution within the J&J conglomerate.
View full company profileAbout johnson-and-johnson-innovative-medicine
Johnson & Johnson Innovative Medicine, established as a clarified entity in 2023 following the Kenvue spin-off, is a global pharmaceutical leader with a mission to transform healthcare through high-impact science. Its strategy integrates deep internal R&D with strategic business development to build a leading pipeline across oncology, immunology, neuroscience, and cardiopulmonary diseases. Recent achievements include the FDA approval of the first-in-class oral peptide ICOTYDE™ for psoriasis and the expansion of its multiple myeloma regimen, demonstrating its capacity for innovation and commercial execution within the J&J conglomerate.
View full company profileAbout Johnson & Johnson
Johnson & Johnson is a diversified healthcare leader with a mission to prevent, treat, and cure complex diseases through smarter, less invasive, and more personalized solutions. Its strategic pivot to a pure-play Innovative Medicine and MedTech structure enhances focus and capital allocation towards high-margin, innovative therapies and advanced technologies. The company sustains its leadership through a formidable R&D engine, a robust commercial portfolio featuring multiple blockbuster drugs, and a disciplined strategy of strategic business development and portfolio optimization.
View full company profileAbout Johnson & Johnson
Johnson & Johnson is a diversified healthcare leader with a mission to prevent, treat, and cure complex diseases through smarter, less invasive, and more personalized solutions. Its strategic pivot to a pure-play Innovative Medicine and MedTech structure enhances focus and capital allocation towards high-margin, innovative therapies and advanced technologies. The company sustains its leadership through a formidable R&D engine, a robust commercial portfolio featuring multiple blockbuster drugs, and a disciplined strategy of strategic business development and portfolio optimization.
View full company profileTherapeutic Areas
Other Systemic Lupus Erythematosus (SLE) Drugs
| Drug | Company | Phase |
|---|---|---|
| hCDR1 (Edratide) | XTL Biopharmaceuticals | Phase 2 |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| IFNα Kinoid (IFN-K) | Neovacs | Phase IIb |
| Brepocitinib (PF-06700841) | Priovant Therapeutics | Phase 3 |
| aiSLE® DX Flare Risk Index | Progentec Diagnostics | Commercial |
| aiSLE® DX Disease Activity Index | Progentec Diagnostics | Commercial |
| OASIS Study (Digital Biomarkers) | Progentec Diagnostics | Clinical Study |
| RSLV-132 | Resolve Therapeutics | Phase 2 |
| Mini-CAR for SLE | Caravan Biologix | Pre-clinical |
| Internal Program | BenevolentAI | Preclinical |
| Telitacicept (RC18) | RemeGen | Approved |
| Cenerimod | Ono Pharmaceutical | Phase 3 |